Conference abstractPublished 24 Aug 2015
A toxicokinetic model of acute myelolytic leukemia for testing chemopreventive efficacy of cancer preventing drugs
University of Kalyani, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To develop a toxicokinetic model of acute myelolytic leukemia, benzene was used as a potent leukemogenic agent. The dose, period and time of cumulative benzene exposure of Swiss Albino mice were optimized and survival rate; alteration in cell cycle regulation and other clinical manifestations were analyzed at a cumulative dose of 300ppm × 6 hr. /day × 5 days/week for 2 weeks, i.e., 9000(a) ppm. Analyzing physiological parameters like plasma enzyme profile, complete hematology (Hb %, RBC indices and WBC differentials), hematopoietic cells morphology, expression of cell cycle regulatory proteins, tissue histology and analysis of DNA fragmentation, optimum conditions were established. Elevated level of Plasma AST/ALT with corresponding changes in liver histology of optimally exposed animals also confirmed the toxicokinetic relation of benzne with leukemia. Down regulation of p53 and p21 and up regulation of CDK2, CDK4, CDK6, cyclin D1 and E in this exposed group were marked as the optimum conditions of cellular deregulation for the development of secondary AML. The efficacy of this in vivo model has been tested for chemopreventive activity of two natural phytochemicals like catechin. a natural phenol and antioxidant from Saraca asoca (Roxb.) and monotarpenes from Ocimum basilicum L comparing with known chemotherapeutic drug doxorubicin. It has been concluded that this toxicokinetic model can be utilized as a testing template for the development of multiactive drugs for cancer chemoprevention in the near future.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectHaematology
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Debjani Nath”
